AOD-9604 in Junction — Fat Loss Peptide Research Guide
AOD-9604 research guide for Junction. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Unlike common nutraceuticals stocked in every health store, AOD-9604 moves through a global research peptide market that Junction residents access almost entirely online. This online-only market structure is ultimately a quality advantage — top vendors distinguish themselves through rigorous testing in ways brick-and-mortar outlets simply cannot. Separating genuine research-grade AOD-9604 from the rest of the market comes down to three things: an HPLC chromatogram confirming ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. This guide gives Junction researchers the methodology to assess vendor quality rigorously and source high-purity AOD-9604 with confidence.
Understanding AOD-9604 — Biology & Evidence
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Junction studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Where to Buy AOD-9604 — A Researcher's Guide
Assessing AOD-9604 vendors begins with the COA: locate the batch-specific certificate prior to buying, not after. When reviewing a AOD-9604 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are at acceptable levels for the intended application. Signs of a credible vendor beyond COA quality: multi-year operating history, knowledgeable support capable of explaining COA data, and shipping with desiccant and appropriate cold protection. For Junction researchers making a first AOD-9604 purchase: apply these quality criteria before ordering, begin with a small order, and check that batch numbers on your vial match the COA before use.
Order AOD-9604 — ships to Junction
COA-verified · International tracking · Research grade
All use of AOD-9604 in Junction or anywhere must be research use only — this compound is not approved for human therapeutic use, and all handling should adhere to research compound handling standards. Storage requirements for AOD-9604: lyophilised powder at freezer temperature, reconstituted solution refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with bac water. Bacterial endotoxin contamination is the primary safety concern specific to research peptides — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. The research literature on AOD-9604 should be reviewed carefully before beginning any research — study methodologies, dosing, and endpoints vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
